As tensions in trade between the U.S. and China appear to be diminishing, Asian markets are gaining optimism, especially in the tech sector, where growth potential remains strong. In this context, pinpointing high-growth tech stocks requires identifying firms that exhibit notable innovation and flexibility, along with the capability to prosper amidst changing global economic landscapes.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Suzhou TFC Optical Communication |
29.85% |
28.85% |
★★★★★★ |
|
Fositek |
31.52% |
37.08% |
★★★★★★ |
|
Delton Technology (Guangzhou) |
21.21% |
24.38% |
★★★★★★ |
|
Range Intelligent Computing Technology Group |
31.40% |
31.62% |
★★★★★★ |
Let’s explore some key selections from our screened stocks.
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of antibody drugs, with a market cap of HK$88.77 billion.
The company generates revenue mainly from biopharmaceutical products, totaling CN¥2.12 billion. Recently, Akeso achieved critical regulatory milestones, enhancing its potential within Asia’s high-growth tech sectors. Its PD-1/VEGF bispecific antibody, ivonescimab, secured NMPA approval for first-line treatment of non-small cell lung cancer (NSCLC), boasting a progression-free survival rate of 11.14 months. Additionally, its FDA-approved penpulimab-kcqx for treating nasopharyngeal carcinoma signifies robust international expansion and innovative drug development capabilities. These advancements position Akeso strongly in the competitive oncology market, with annual revenue growth projected at 29.3% and expectations of reaching profitability in three years.
